The global market for microbial identification market is expected to grow at a CAGR of 13.2% during the forecast period of 2023 to 2030. The rising prevalence of infectious diseases and the rising frequency of pandemics, technological advancements, increasing concerns regarding food safety, and increasing government initiatives and funding to detect and control antimicrobial-resistant species are the primary factors driving the growth of this market. Microorganisms, which include bacteria, yeasts, and moulds, have been essential to the continued existence of humans ever since the beginning of time. In a manner that is analogous to how they were in the past, they are intricately connected to the fields of medicine, biotechnology, and genetic engineering, amongst other fields. They are utilised because of their one-of-a-kind properties, which enable the production of food and products related to food, as well as the decomposition of materials such as lignocellulosic biomass as a source of second-generation ethanol or biogas, amino acids, antibiotics, hormones, and other therapeutic compounds. This allows for the production of food and products related to food. At the same time, some genetic properties and metabolic powers of bacteria make them dangerous not only to industry (the spoiling of food) but also to human health.

The global microbial identification market is being driven by a number of factors, including advances in technology that increase the speed and accuracy of microbial identification equipment, an increase in the number of diseases caused by harmful microorganisms, and stricter regulations regarding food safety. In addition, the attention of pharmaceutical companies has been drawn to the use of microbial identification as a tool for analysing how various medications behave in response to the presence of particular bacteria. From this point forward, it is anticipated that the total revenues garnered by the Microbial Identification Market across the globe would see enormous growth. The report on the Global Microbial Identification Market is an analysis that takes into account all aspects of the market. The research provides an in-depth analysis of the market's most important segments, trends, drivers, and constraints, as well as the competitive landscape and factors that are having a significant impact on the industry.

Transition Towards Genotypic Identification Approach

One of the most noticeable trends that have been noted in the process of expanding the market for microbial identification around the world is a shift in preference toward the genotypic identification approach. Because it is based on nucleic acid analysis, the genotypic approach to microbial identification is more accurate and dependable than other methods. This can be explained by the fact that it is more accurate. In addition, one of the primary contributors to the expansion of the market for microbial identification is the continuing acceleration of technological progress. When compared to more traditional forms of testing, the identification of microorganisms is now more precise, expedient, and accurate because of the application of technologically advanced technologies. These techniques give a high throughput rate while being relatively low in cost. For example, the MALDI-TOF method is commonly used since it generates results in a shorter amount of time, requires fewer consumables, and has a lower overall cost. Additionally, the high incidence rate of infectious diseases, rising incomes that are disposable, and measures taken by the government are all favourably predicted to fuel the growth of the global microbial identification market.

The Rising Prevalence of Infectious Diseases and The Increased Likelihood of Pandemics Remain as the Key Drivers

Human disease diagnosis is the most common application for microbiological identification. It generates results in a fast manner that is both speedy and reliable, which assists in the timely adoption of relevant therapies. The management of infectious diseases can be improved with the use of products for the identification of microorganisms, particularly in regions with insufficient healthcare infrastructure. It is believed that roughly 1,400 different pathogens have the potential to cause disease in humans. There are approximately 350 million cases of foodborne infections that are solely caused by pathogenic bacteria. Just in the United States alone, there are around 48 million cases of foodborne disease each year, which results in approximately 128,000 hospitalizations and 3,000 fatalities each year. Inadequate water hygiene is responsible for around 1.7 million deaths each year around the world; the majority of these fatalities occur in children. The vast majority of these deaths, on the other hand, are recorded in developing nations (NCBI). There has been a discernible rise, throughout the course of the years, in the prevalence of infectious diseases found all over the world. The World Health Organization (WHO) identifies tuberculosis as one of the top 10 leading causes of death. In 2018, tuberculosis was responsible for the deaths of 1.5 million individuals around the world. The detection and treatment of tuberculosis are credited with saving an estimated 58 million lives between the years 2000 and 2018. According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), there were 1.7 million new cases of HIV infection worldwide in 2019, 38 million individuals are currently living with HIV, and 690,000 people passed away as a result of AIDS-related illnesses. In addition, events such as the Zika pandemic in 2016, the Ebola pandemic in 2014, the H1N1 swine flu pandemic in 2009, the H5N1 avian flu pandemic in 2004, the severe acute respiratory syndrome (SARS) pandemic in 2003, and the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic in 2019–2020 have prompted significant worries regarding public health. They also result in a rise in the need for diagnostic items, especially those used for the detection of microorganisms. Therefore, factors such as the high prevalence and incidence of various infectious diseases as well as the rising frequency of pandemics are driving growth in the market for microbial identification.

Emerging Technologies to Boost the Market Expansion

The methods used to identify clinically relevant bacteria have seen enormous leaps and bounds forward in recent years. Over the course of years, there has been a slow but steady expansion of the range of organisms that can be identified, leading to greater inclusion of a wider variety of strains of microorganisms. One example of this is the use of mass spectrometry (MS) in clinical specimens, which allows for a more expedient identification of isolated organisms. There have been at least 30 new diseases discovered in the past 20 years, as stated by the World Health Organization. These diseases now pose a risk to the health of hundreds of millions of people around the world. It is becoming more important to pinpoint the specific bacterium responsible for infectious diseases as the number of people affected by these diseases continues to rise. This element is one of the contributors to the expansion of the market sector. The methodologies of mass spectrometry (MS), polymerase chain reaction (PCR), and time-of-flight mass spectrometry are the foundations for the development of the apparatus used to identify microorganisms (TOF-MS). However, these highly developed technologies for the identification of microorganisms are not readily available everywhere in the world. During the forecast period, it is anticipated that such technologies will be largely accessible.

The ability of the pharmaceutical business to provide solutions to the challenges faced by modern medicine is what will determine the sector's level of development and usefulness. The pharmaceutical industry has recognised the value of microbial identification as a tool for promoting innovation in medication research and development. In addition, the attention of pharmaceutical makers has been drawn to the practice of using microbial identification in order to research the effect of various medications on particular microorganisms. s a consequence of this, it is anticipated that the overall volume of revenues generated within the global market for microbial identification would expand by several leaps. The investigation of human DNA, particularly how it differs from the DNA of other species and how this relates to the detection of microbes.
 
The High Price of Fully Automated Microbiological Identification Technologies Is a Limitation.

Automated instruments for the identification of microorganisms come packed with extremely cutting-edge features and functions, and their prices reflect this level of sophistication. The cost of a system that is based on MALDI-TOF might range anywhere from US $150,000 to US $850,000. In addition to the high expense of the labour involved, the consumables that are required for identification procedures are also quite pricey. The price of many of the new fast tests is normally between US $100 and US $250; this places them at a significant premium in comparison to the traditional cultural procedures. For some end users, the estimated cost of the equipment, media, and labour is prohibitively expensive.

The cost of automated microbial identification systems typically falls around between US $50,000 and US $75,000. Because pharmaceutical businesses need a large number of these types of equipment, their capital expenditures are greatly increased. Because of their limited budgets, academic research laboratories almost never have the funds necessary to purchase such systems. Additionally, an increase in the total cost of ownership of these instruments is brought about as a result of the costs associated with maintenance as well as a number of other indirect charges. This makes it more difficult for automated microbial identification techniques to gain widespread use, particularly among relatively modest organisations.

Regulatory Framework Slowing the Market Growth

It is also anticipated that growth will be slowed throughout the projected period as a result of complicated regulatory frameworks that cause delays in the approval of novel microbiological diagnostic tests. Despite this, the expansion of the Microbial Identification Market is anticipated to be primarily driven by developments in technology, the surveillance of bioterrorism, and growing economies. The existing procedure for FDA approval of devices and consumables is very time-consuming and difficult to understand. The previous In Vitro Diagnostic Devices Directive (IVDD) 98/79/EC was repealed and replaced with the brand new In Vitro Diagnostic Device Regulation (IVDR), which was published by the Council of the European Union in May of 2016. In 2017, the European Council made the IVDR mandatory for all member states. IVDR will be subject to the new regulations beginning in May 2023. The transition period for businesses to become compliant with the new regulations is five years. These restrictions are both more complicated and more stringent. Because of this, market participants will find it difficult to align their processes with the new laws, which can have a momentary impact on the amount of time needed to bring new products to market, particularly in the United States and Europe. The global market for microbial identification stands to benefit immensely from the prospects presented by this development. The stringent regulatory clearances and turnaround times could be a potential barrier to the market's expansion during the duration of the given projection.

Technological Drawbacks to Hinder the Market Expansion

In addition, erroneous conclusions can be caused by a lack of sufficient sample size, the non-homogeneous distribution of microbes across the majority of food matrices and habitats, and the influence of non-random sampling. All of these factors can have an effect. In addition, although the results of microbiological testing typically identify outcomes, they may not always show the sources or controls of contamination that are associated with those outcomes.

Emerging Economies Promise Significant Opportunities During the Forecast Period

It is anticipated that emerging economies would become a primary driving force behind the expansion of the market for microbiological identification. In comparison to Europe and North America, the Asia Pacific, Middle Eastern, and Latin American countries all represent relatively untapped opportunities for businesses that specialise in the identification of microorganisms. As a result of this, the governments of a number of Asian nations are providing financial assistance to ensure the continued growth of the market for microbial identification. In this regard, numerous initiatives have been launched in Asia by international organisations, including the following:

• Australia's next national antimicrobial resistance plan will be published in 2020 with COAG approval. Australia's National Antimicrobial Resistance Strategy - 2020 and beyond puts out a strategy for the next 20 years to preserve human, animal, and environmental health by minimising AMR while keeping access to effective antimicrobials.
• In 2019, Thermo Fisher Scientific (US) opened a food safety customer solution centre in Delhi, India. The new centre aims to meet the demands of food and beverage lab scientists by establishing crucial workflows and integrated solutions that expand India's food safety capabilities. In 2017, India's Ministry of Health and Family Welfare unveiled a plan to eliminate tuberculosis (TB) (2017–2025). The initiative aims to eliminate TB by 2025. The strategy aims to reduce tuberculosis incidence and death in India by 2025.
• China has developed national measures to tackle antimicrobial resistance (AMR) in recent years. The NAP to Contain Antimicrobial Resistance is one initiative (2016–2020). The NAP has identified its funding source, built a monitoring and evaluation mechanism, and is being implemented.

Technological Advances are to Offer Huge Market Potential

Mass spectrometry, also known as MS, is a potent approach for collecting ever-more-detailed insights on alterations to a proteome, which is necessary for the production of individualised therapies. The sensitivity of MS has increased in recent years, which has led to the discovery of novel types of tumour-specific proteoforms. The overlap of proteomic data with genomic data and transcriptome data gives rise to the rapidly developing field of proteogenomics, which has the potential to deepen our understanding of the development of tumours. Proteogenomics has the potential to deepen our understanding of how tumours form. Overall, these new advancements serve to both substantiate the significance of the role that MS-based clinical proteomics plays in cancer research and hasten the process by which it will eventually become an integral component of clinical diagnosis and treatment.

Additionally, robots, microfluidics, and nanotechnology have aided in the rapid advancement of new methods by mechanising various components of the PCR test. This improvement has been made possible by the mechanisation of previously manual processes. Real-time polymerase chain reaction (PCR), DNA microarrays, and DNA chips all make use of these more contemporary methods, in conjunction with computers and computer programmes.

PCR assay equipment that can be used hand-held is currently under development. In particular for infectious agents that are difficult to detect or validate, the PCR and reverse transcription-PCR (RT-PCR) procedures have considerably sped and improved the accuracy of disease diagnosis in both humans and animals. The polymerase chain reaction (PCR) approach has made it possible to swiftly and cheaply characterise the genetic makeup of microbiological isolates for the purposes of identification, typing, and epidemiological comparison.
 
Instruments Segment to Continue its Dominance During the Forecast Period

The instrument segment held the dominant position in 2021 and, the instruments subsegment will continue to hold the greatest revenue share even during the forecast period. The need for instruments is being driven by a number of variables, the majority of which are attributable to the numerous technological breakthroughs that have been made in microbial identification systems. The rapid and accurate detection of pathogenic microorganisms that have been isolated from samples of food is essential for both the monitoring of food quality and the tracking of bacterial outbreaks that have occurred within the food chain. In clinical and food microbiology laboratories, automated technologies for the identification of microorganisms are becoming an increasingly common practice. These systems provide a number of major advantages over more conventional methods, including a reduction in the amount of labour required, a reduction in the amount of human error, a higher sample throughput, and faster turnaround times for test results. A CAGR of 14% is anticipated for bacterial identification systems during the forecast period. By the end of the forecast period (2030), these systems are projected to hold a revenue share of approximately 30%. 

Market by Method: Phenotypic Segment held the Lion’s Share

The phenotypic sector held the lion's share in 2021 with a revenue share of about 55%. They are able to recognise a wide range of taxonomic groups, identify resistance that is being actively expressed, and tolerate genetic variability in resistance identification. The demand for this segment is being fuelled by the factors that can be attributed to the widespread utilisation of phenotypic methods for the identification of microorganisms in a variety of industries, including the healthcare industry, the food and beverage industry, the pharmaceutical industry, and the environmental industry.

Diagnostic Application Remains as the Revenue Leader While Pharmaceutical to be the Growth Leader

In the year 2021, diagnostic applications held the highest market share of about 33%. Sales in the overall microbial identification market are being driven upward by rising rates of acute and chronic infections, food-borne diseases, and other similar conditions. It is anticipated that the pharmaceutical applications sector would evidence the highest CAGR during the forecast period. The factors that can be attributed to the rise in the number of pharmaceutical companies to meet the increased demand for novel drugs are critical factors that will upsurge the industry's contribution to the global Microbial Identification Market. Another factor that will upsurge the industry's contribution is an increase in the number of infectious diseases.

Market By Consumables: Panels, ID Cards, And Media Dominated the Market

Consumables such as panels, ID cards, and media accounted for the largest portion of the market share in 2021. Microorganisms may be identified in a simple and quick manner thanks to panels, ID cards, and other media, which are one of the primary drivers driving the market growth.

Mass Spectrometry Leading the Technologies Market

Due to its high speed, high specificity, and application for a wide range of microorganisms such as bacteria, archaea, and fungi, the mass spectrometry segment accounted for the biggest share in 2021. In addition, it was the segment that had the highest CAGR during the forecast period. Another important factor contributing to the expansion of the market is the expanding use of MALDI-TOF technology for the identification of microorganisms.

North America Remains the Global Leader

In 2021, the market for microbial identification was led by North America, which accounted for the biggest share. The major drivers of the North American market are technological advancements in microbial identification, an increasing prevalence of infectious diseases, growing concerns about food safety, and the presence of prominent players. It is anticipated that the U.S. will continue to experience strong growth during the forecast period, which will allow it to maintain its dominant position in the North American region with a total market share of approximately 85% in 2021.

Since its introduction in 1991 as a rapid, accurate, and cost-effective method for identifying more than 1,500 different microbial species, fatty acids, and PLFAs through the use of GC-FAME analysis, the Sherlock Microbial Identification System (MIS) has garnered an increasing amount of recognition in the U.S. The Sherlock MIS is recognised by the U.S. Centres for Disease Control and Prevention (CDC) for the identification of aerobic bacteria, and it has received approval from the Association of Official Analytical Chemists (AOAC) International for the identification of Bacillus anthracis, the anthrax pathogen. This is one of the most important factors contributing to the development of the market for identifying microorganisms within the country.

The Asia Pacific is expected to be the fastest-growing market during the forecast period of 2023 to 2030. China is expected to grow at a healthy compound annual growth rate (CAGR) of 10% over the course of the forecast period, while also holding approximately 52% of the market share in Asia in 2021. The market in the country will be boosted as a result of an increasing number of FDA approvals in China, an increase in innovative strategies for technological advancements in the field, and geographical emergence by manufacturers.

Europe remained the second largest market following the U.S. in 2021.  In the European market for microbial identification over the course of the forecast period, it is anticipated that Germany will exhibit a CAGR of nearly 9.5%. During the forecast period, the expansion of the market for microbial identification in Germany will be supported by the intense focus that the pharmaceutical industry places on research operations to develop novel treatments and vaccines.

Focus on Opportunity Markets to Offer Competitive Advantage in this Fragment Market

The market is extremely fragmented due to the presence of various competitors operating in this segment. These businesses are pursuing strategies such as mergers and acquisitions, partnerships and collaborations, and the introduction of new products in order to satisfy the demand of their customers and increase the size of their existing customer base. The most dominant companies in the market include Thermofisher Scientific, BioMérieux SA, Beckman Coulter Inc., Shimadzu Corporation, and Becton, Dickinson and Company. There are also a number of regional and smaller businesses that represent a large portion of the market. Market vendors are concentrating more on the growth prospects in the rapidly expanding segments in order to make the most of the opportunities and recover from the impact of the pandemic. At the same time, they are working to maintain their positions in the slowly expanding segments.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Pharma Microbial Identification market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Pharma Microbial Identification market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Pharma Microbial Identification market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Pharma Microbial Identification market?
• Which is the largest regional market for Pharma Microbial Identification market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Pharma Microbial Identification market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Pharma Microbial Identification market worldwide?